无创胎儿血型基因型检测的应用进展  

Improvements of non-invasive methods to genotyped fetal ABO and RhD blood group

作　　者：张建军[1] 曾艳[1] 

机构地区：[1]绍兴市妇幼保健院,浙江312000

出　　处：《中国优生与遗传杂志》2018年第1期1-3,共3页Chinese Journal of Birth Health & Heredity

摘　　要：新生儿溶血病是由于胎儿与母亲红细胞血型不合引起的免疫性溶血性疾病,临床上最常见的是胎儿与母亲的ABO血型或RhD血型不合,产前检测胎儿的ABO和RhD血型十分重要。目前,用孕妇外周血血浆提取胎儿游离DNA来产前检测胎儿的ABO和RhD基因型的方法取得了很大进展,本文就无创胎儿ABO和RhD血型基因型检测的进展进行综述。Hemolytic disease of the newborn（HDN）is the hemolytic disease,due to the mismatch of red blood cell between mothers and fetus,the most common cause is the mismatch of ABO and RhD between the mothers and fetus.It is important to predict the incidence of HDN by prenatal detectiing of fetal ABO and RhD blood group.During the recent years,the methods of using the cell-free fetal DNA in maternal blood to prenatally detecting fetal ABO and RhD blood genotype was improved dramatically and used in clinical.This article is a summary of the improvements of non-invasive methods to genotyped fetal ABO and RhD blood group.

关 键 词：基因型 胎儿游离DNA 新生儿溶血病 血型 无创 

分 类 号：R722.1[医药卫生—儿科]